CCDC74A: A Potential Drug Target and Biomarker for the Treatment of Cancer

Target Name: CCDC74A

NCBI ID: G90557

CCDC74A

CCDC74A: A Potential Drug Target and Biomarker for the Treatment of Cancer

Introduction

CCDC74A, also known as CCDC74A variant 1, is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, kidneys, and gastrointestinal tract. Its primary function is to regulate cell growth and differentiation, and it has been associated with the development and progression of several types of cancer. In recent years, researchers have become increasingly interested in CCDC74A as a potential drug target and biomarker for cancer treatment. In this article, we will explore the biology and potential therapeutic applications of CCDC74A.

The biology of CCDC74A

CCDC74A is a member of the transforming growth factor-beta (TGF-β) family, which is a group of proteins that play a critical role in cell growth, differentiation, and survival. The TGF-β family consists of several subfamilies, including TGF -尾1, TGF-β2, TGF-β3, and TGF-β4. These subfamilies are involved in the regulation of cell growth, cell type specification, and tissue development.

One of the functions of CCDC74A is to regulate the activity of the TGF-β1 subfamily. This subfamily is involved in the regulation of cell growth, cell-cell adhesion, and angiogenesis (the formation of new blood vessels). CCDC74A has been shown to play a role in the regulation of TGF-β1 activity by inhibiting its activity on the receptor FGF-1.

In addition to its role in regulating TGF-β1 activity, CCDC74A has also been shown to be involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together and form tissues. CCDC74A has also been shown to play a role in the Regulation of cell-cell adhesion by interacting with the protein PDGFR (Programmed death-ligand 1).

Potential therapeutic applications of CCDC74A

The therapeutic potential applications of CCDC74A are vast and varied. In cancer treatment, CCDC74A has been shown to be involved in the regulation of cell growth, cell-cell adhesion, and angiogenesis, which are all critical processes that are often disrupted in cancer cells. As a result, CCDC74A has the potential to be a useful drug target for cancer treatment.

One of the key advantages of CCDC74A as a drug target is its ubiquitous expression in various tissues of the body, which makes it a potential target for small molecules that can be used to inhibit its activity. In addition, CCDC74A is involved in several critical processes that are involved in cancer progression, such as cell growth, angiogenesis, and the regulation of cell-cell adhesion. This means that targeting CCDC74A with small molecules or other therapeutic agents has the potential to disrupt the growth and survival of cancer cells.

Another therapeutic potential application of CCDC74A is its involvement in the regulation of TGF-β1 activity. TGF-β1 is a key regulator of cell growth, differentiation, and survival, and its activity is often disrupted in cancer cells. By targeting CCDC74A with small molecules or other therapeutic agents, researchers may be able to restore TGF-β1 activity in cancer cells, which could have a therapeutic effect on cancer growth and progression.

In addition to its potential therapeutic applications, CCDC74A is also being studied as a potential biomarker for cancer. The regulation of cell growth and differentiation by TGF-β1 is a critical process that is involved in the development and progression of cancer. As a result, the activity of CCDC74A

Protein Name: Coiled-coil Domain Containing 74A

The "CCDC74A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC74A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets